RecruitingNot ApplicableNCT07022067
EVOLVING AZIMUTH IN MUSA CONTEXT
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Enrollment
184 participants
Start Date
Oct 2, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Non-pharmacological, randomized, nonprofit medical device intervention. The study aims to identify the positive impacts (co-creation), and negative impacts (co-destruction), resulting from the use of telemedicine, and, in particular, the telemonitoring service for patients with heart failure
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Have been diagnosed with chronic CS according to the ESC guidelines;
- Over 18 years of age;
- Patients admitted to hospital or with access to first aid within the last year;
- Smartphome that meets the digital requirements (ie Android or iOS able to download and use the application);
- Wi-Fi or 3G coverage at home;
- Ability to give written informed consent.
Exclusion Criteria4
- Severe psychiatric disorder
- Inability to use portable technologies
- Patients unable to use the equipment provided
- Patients who deny consent to study participation
Interventions
DEVICETelemonitoring app
periodic measurement of blood pressure and body weight
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07022067
Related Trials
Mind Your Heart-II
NCT054311921 location
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations